Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced Monday that it has secured the winning bid in the bankruptcy auction ...

Regeneron announced a plan to acquire genetic testing firm 23andMe through bankruptcy court, including access to personal ...

Genetic testing company 23andMe isn’t going away, despite declaring bankruptcy. The company and nearly all of its assets, ...

On Monday, Regeneron Pharmaceuticals announced that it would acquire most of 23andMe's assets for $256 million. According to ...

South San Francisco, California-based 23andMe filed for bankruptcy last month, seeking to sell its business at auction after ...

Regeneron to rescue 23andMe in a $256 million deal, raising major questions about DNA privacy, genetic data ownership, and ...

Co-founder Anne Wojcicki resigned in March and attempted to bid for the company independently ... revoking permissions amid ...

The insolvent genetic analysis company 23andme is taken over by a pharmaceutical company that wants to continue the business ...

Regeneron to acquire nearly all of 23andMe’s assets for $256M, marking a new chapter for the direct-to-consumer genetic testing pioneer.

The company has signed up to pay $256 million for 23andMe and nearly all of its assets, including its R&D services operations ...

The biotech, which has for years invested in genetics research, plans to acquire "substantially all" of testing firm ...

DB-OTO, which Regeneron obtained from the 2023 acquisition of Decibel Therapeutics for $109 million, works by delivering a ...